SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 24, 2022

Primary Completion Date

June 25, 2023

Study Completion Date

May 31, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
RADIATION

SBRT

Stereotactic body radiation therapy delivered with a fixed dose (8Gy) in 3 daily fractions 1-7 days before the first cycle of immunochemotherapy

DRUG

Tislelizumab

200mg q3w for two cycles administrated concurrently with chemotherapy

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER